LENZ Therapeutics (LENZ) Asset Writedowns and Impairment (2023 - 2025)
LENZ Therapeutics' (LENZ) quarterly Asset Writedowns and Impairment came in at $82000.0 in Q2 2025, down 99.39% on a QoQ basis from $13.3 million in Q4 2023.
LENZ Therapeutics (LENZ) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
LENZ Therapeutics (LENZ) has 2 years of Asset Writedowns and Impairment data on file, last reported at $82000.0 in Q2 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $82000.0 in Q2 2025; TTM through Mar 2026 was $82000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $82000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q2 2025 stood at $82000.0, down from $13.3 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for LENZ reached as high as $13.3 million in Q4 2023 and fell as low as $82000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn |
| 10 | LENZ Therapeutics | 181.38 Mn | -77.01 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Dec 31, 2023 | 13.35 Mn |
| Dec 31, 2023 | 13.35 Mn |
| Sep 30, 2023 | 7.22 Mn |
| Sep 30, 2023 | 7.22 Mn |